Irinotel 100 mg Inj

Irinotecan belongs to a class of chemotherapy medications known as topoisomerase inhibitors, which work by blocking an enzyme called topoisomerase I, essential for cancer cells to properly unwind and replicate their DNA during division. By disrupting this process, Irinotecan helps prevent cancer cells from dividing effectively, ultimately slowing tumor growth and progression. It is commonly used in the treatment of colorectal cancer, often as part of a combination chemotherapy regimen alongside other agents such as fluorouracil and leucovorin, in a widely used protocol known as FOLFIRI. Irinotecan is also used in certain other gastrointestinal cancers and some cases of lung cancer, working alongside complementary medications to target cancer cells through multiple mechanisms. The medication is administered through intravenous infusion, typically in a hospital or specialized oncology setting, allowing healthcare providers to closely monitor the patient during and after administration. Treatment schedules and dosing are carefully individualized based on the specific type and stage of cancer, as well as the patient's overall health and treatment history. Regular monitoring, including blood counts and digestive symptom assessment, is an important part of care throughout treatment to help guide safe and effective dosing. Many patients experience meaningful tumor response and improved disease management as part of a comprehensive cancer treatment plan involving Irinotecan. As with all chemotherapy medications, Irinotecan injection should be administered under the close supervision of an experienced oncology healthcare team.